◎ Sugi Atlas

Atlas / Drug / Prednisolone

Prednisolone

drug
On this page

Also known as CortaloneDekotilDelta-cortefDeltacortrilDeltaloneDilacortEquisolonFernisolone-pHydeltraMeti-dermNSC-9120NSC-9900Neo-delta-cortefPevantiPrecortisylPrecortisyl ftePrednisolonaPrelonePoly-pred

Summary

Prednisolone (CHEMBL131) is an approved small-molecule adrenergic agent (ATC S02BA03) targeting NR3C1 and NR3C2; indicated across 160 conditions including eye disorder and nephrotic syndrome; with CIViC clinical evidence for 3 variant-indication associations (e.g. NT5C2 R238W in childhood acute lymphocytic leukemia).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: S02BA03 (+12 more)
  • Targets: 2 (NR3C1, NR3C2)
  • Indications: 160 conditions
  • Clinical trials: 506
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 360.4 Da · C21H28O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL131
NamePrednisolone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5755
ChEBICHEBI:8378
ATCS02BA03, D07XA02, R01AD02, A01AC04, D07AA03, R01AD52, C05AA04, S03BA02, A07EA01, H02AB06, A01AC54, S01BA04, S01CB02
Molecular formulaC21H28O5
Molecular weight360.4
InChIKeyOIGNJSKKLXVSLS-VWUMJDOOSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O

IUPAC name: (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

ChEBI definition: A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding β-hydroxy group. It is a drug metabolite of prednisone.

Pharmacological roles (ChEBI): adrenergic agent, anti-inflammatory drug, antineoplastic agent, immunosuppressive agent.

Other ChEBI roles (chemical / environmental): drug metabolite, environmental contaminant, xenobiotic.

Also known as: Cortalone, Dekotil, Delta-cortef, Deltacortril, Deltalone, Dilacort, Equisolon, Fernisolone-p, Hydeltra, Meti-derm, NSC-9120, NSC-9900

Patent coverage: 36,298 distinct patent families (140,604 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorFull agonist8.150.9%P04150
NR3C2Mineralocorticoid receptorAgonist7.430%P08235

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Interleukin-6, Tumor necrosis factor, Androgen receptor, Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Corticosteroid-binding globulin, Glucocorticoid receptor, Glucocorticoid receptor, Disintegrin and metalloproteinase domain-containing protein 17.

Bioactivity

ChEMBL activities: 122 potent at pChembl ≥ 5 of 125 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C29.54Ki0.29nMCHEMBL_ACT_13934673
NR3C19.28IC500.53nMCHEMBL_ACT_16353808
NR3C18.94Ki1.14nMCHEMBL_ACT_13934697
NR3C18.82Ki1.5nMCHEMBL_ACT_2517717
NR3C18.82Ki1.5nMCHEMBL_ACT_6275755
NR3C18.82Ki1.5nMCHEMBL_ACT_7848728
NR3C28.7EC502nMCHEMBL_ACT_6276530
NR3C18.68IC502.1nMCHEMBL_ACT_1044970
NR3C18.68EC502.1nMCHEMBL_ACT_208923
NR3C18.68IC502.1nMCHEMBL_ACT_801758
NR3C18.62Ki2.4nMCHEMBL_ACT_1044965
NR3C18.62Ki2.4nMCHEMBL_ACT_208920
NR3C18.62Ki2.4nMCHEMBL_ACT_3252323
NR3C18.62Ki2.4nMCHEMBL_ACT_419084
NR3C18.59EC502.6nMCHEMBL_ACT_419088
NR3C18.52EC503nMCHEMBL_ACT_3298658
NR3C18.48EC503.3nMCHEMBL_ACT_419086
P065378.47EC503.4nMCHEMBL_ACT_1521471
NR3C18.47EC503.4nMCHEMBL_ACT_1961489
NR3C18.42IC503.8nMCHEMBL_ACT_1044972
NR3C18.4ED504nMCHEMBL_ACT_2150546
NR3C18.39IC504.1nMCHEMBL_ACT_1970219
NR3C18.39IC504.1nMCHEMBL_ACT_2174109
NR3C18.39IC504.1nMCHEMBL_ACT_5122334
NR3C18.39IC504.1nMCHEMBL_ACT_5246651
NR3C18.39IC504.1nMCHEMBL_ACT_5251404
NR3C18.39IC504.1nMCHEMBL_ACT_6150089
IL68.38IC504.2nMCHEMBL_ACT_16339615
NR3C18.35EC504.5nMCHEMBL_ACT_1521468
NR3C18.35EC504.5nMCHEMBL_ACT_1961363

Target pathways

Aggregated over 2 target gene(s): NR3C1, NR3C2.

Top Reactome pathways

14 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand2NR3C1, NR3C2
Nuclear Receptor transcription pathway2NR3C1, NR3C2
SUMOylation of intracellular receptors2NR3C1, NR3C2
Cellular responses to stress1NR3C2
SUMOylation1NR3C2
SUMO E3 ligases SUMOylate target proteins1NR3C2
Metabolism of proteins1NR3C2
Post-translational protein modification1NR3C2
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
Cellular responses to stimuli1NR3C2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
regulation of DNA-templated transcription2
regulation of transcription by RNA polymerase II2
signal transduction2
nuclear receptor-mediated steroid hormone signaling pathway2
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
apoptotic process1
chromosome segregation1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

160 indications (58 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
eye disorder4MONDO:0005328EFO:0005752
nephrotic syndrome4MONDO:0005377EFO:0004255
rheumatoid arthritis4MONDO:0008383EFO:0000685
ulcerative colitis4MONDO:0005101EFO:0000729
atopic eczema4MONDO:0004980EFO:0000274
contact dermatitis4MONDO:0005480EFO:0005319
ophthalmic herpes zoster4MONDO:0005883EFO:0007403
frozen shoulder4MONDO:0006763EFO:1000941
iritis4MONDO:0006814EFO:1000997
Crohn disease4MONDO:0005011EFO:0000384
dermatomyositis4MONDO:0016367EFO:0000398
lymphoma4MONDO:0005062EFO:0000574
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
dermatitis herpetiformis4MONDO:0015614EFO:1000684
aplastic anemia4MONDO:0015909HP:0001915
ankylosing spondylitis4MONDO:0005306EFO:0003898
allergic rhinitis4MONDO:0011786EFO:0005854
optic neuritis4MONDO:0005885EFO:0007405
trichinellosis4MONDO:0019444EFO:0007520
psoriasis4MONDO:0005083EFO:0000676
psoriatic arthritis4MONDO:0011849EFO:0003778
non-autoimmune hemolytic anemia4MONDO:0021559EFO:0005558
leukemia4MONDO:0005059EFO:0000565
pneumonia4MONDO:0005249EFO:0003106
meningeal tuberculosis4MONDO:0006042EFO:1000039
subacute thyroiditis4MONDO:0006982EFO:1001194
thrombocytopenia4MONDO:0002049HP:0001873
gout4MONDO:0005393EFO:0004274
atopic conjunctivitis4MONDO:0005642EFO:0007141
pulmonary tuberculosis4MONDO:0006052EFO:1000049
sympathetic ophthalmia4MONDO:0019198EFO:1001205
peptic ulcer disease4MONDO:0004247HP:0004398
erythema multiforme4MONDO:0006545EFO:1000694
seborrheic dermatitis4MONDO:0006608EFO:1000764
mycosis fungoides4MONDO:0009691EFO:1001051
posterior uveitis4MONDO:0006918EFO:1001119
tenosynovitis4MONDO:0004855EFO:1001435
hypercalcemia disease4MONDO:0001566HP:0003072
eosinophilic pneumonia4MONDO:0005749EFO:0007257
synovitis4MONDO:0002400EFO:0008997
keratitis4MONDO:0003085EFO:0009449
exfoliative dermatitis4MONDO:0043233EFO:0009456
hemorrhoid4MONDO:0004872EFO:0009552
myocarditis4MONDO:0004496EFO:0009609
epicondylitis4MONDO:0001875EFO:1001887
iridocyclitis4MONDO:0004773HP:0001094
chorioretinitis4MONDO:0004674HP:0012424
choroiditis4MONDO:0001280MONDO:0001280
chronic primary adrenal insufficiency4MONDO:0015129MONDO:0015128
type III hypersensitivity disease4MONDO:0007004EFO:1001222
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
multiple sclerosis4MONDO:0005301MONDO:0005301
congenital adrenal hyperplasia4MONDO:0018479MONDO:0008728
sarcoidosis4MONDO:0019338MONDO:0019338
systemic lupus erythematosus4MONDO:0007915MONDO:0007915
plasma cell myeloma3MONDO:0009693EFO:0001378
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
IgA glomerulonephritis3MONDO:0005342EFO:0004194
pulpitis3MONDO:0006937EFO:1001139
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
alcoholic hepatitis3MONDO:0001505EFO:1001345
pericarditis3MONDO:0005904EFO:0007427
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
hepatocellular carcinoma3MONDO:0007256EFO:0000182
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
prostate adenocarcinoma3MONDO:0005082EFO:0000673
prostate carcinoma3MONDO:0005159EFO:0001663
kidney disorder3MONDO:0005240EFO:0003086
Kawasaki disease3MONDO:0012727EFO:0004246
lupus nephritis3MONDO:0005556EFO:0005761
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
allergic bronchopulmonary aspergillosis3MONDO:0015243EFO:0007140
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
eosinophilic granulomatosis with polyangiitis3MONDO:0015943EFO:0007208
croup3MONDO:0005722EFO:0007227
autoimmune hemolytic anemia3MONDO:0020108EFO:1001264
hypereosinophilic syndrome3MONDO:0015691EFO:1001467
membranous glomerulonephritis3MONDO:0005376EFO:0004254
anti-neutrophil antibody associated vasculitis3MONDO:0005435EFO:0004826
polymyalgia rheumatica3MONDO:0019735EFO:0008518
habitual spontaneous abortion3MONDO:0006774EFO:1000954
orbital pseudotumor3MONDO:0004769EFO:1001077
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
open-angle glaucoma3MONDO:0005338EFO:0004190
Graves disease3MONDO:0005364EFO:0004237
ocular hypertension3MONDO:0006875EFO:1001069
pure red-cell aplasia3MONDO:0001705MONDO:0001705
glomerulonephritis3MONDO:0002462MONDO:0002462
follicular lymphoma3MONDO:0018906MONDO:0018906
colitis3MONDO:0005292EFO:0003872
focal segmental glomerulosclerosis3MONDO:0100313EFO:0004236
adrenocortical insufficiency3MONDO:0000004EFO:0009491
pemphigus3MONDO:0006594EFO:1000749
eye infectious disorder3MONDO:0043885EFO:1001888
soft tissue sarcoma3MONDO:0018078EFO:1001968
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
cataract3MONDO:0005129MONDO:0005129
allergic disease3MONDO:0005271MONDO:0005271
biliary atresia3MONDO:0008867MONDO:0008867
thrombotic thrombocytopenic purpura3MONDO:0018896MONDO:0018896
stroke disorder3MONDO:0005098EFO:0000712
Takayasu arteritis3MONDO:0017991EFO:1001857
glaucoma3MONDO:0005041MONDO:0005041
graft versus host disease3MONDO:0013730MONDO:0013730
plasma cell neoplasm3MONDO:0004959EFO:0000200
chronic progressive multiple sclerosis3MONDO:0005284EFO:0003840
alcoholic liver disease3MONDO:0043693EFO:0008573
hyperthyroidism3MONDO:0004425EFO:0009189
leprosy2MONDO:0005124EFO:0001054
HIV infectious disease2MONDO:0005109EFO:0000764
canker sore2MONDO:0005318EFO:0003938
hemangioma2MONDO:0006500EFO:1000635
Hodgkins lymphoma2MONDO:0004952EFO:0000183
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
infertility disorder2MONDO:0005047EFO:0000545
melanoma2MONDO:0005105EFO:0000756
celiac disease2MONDO:0005130EFO:0001060
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
chronic kidney disease2MONDO:0005300EFO:0003884
granulomatosis with polyangiitis2MONDO:0012105EFO:0005297
microscopic polyangiitis2MONDO:0019124EFO:1000784
ACTH-dependent Cushing syndrome2MONDO:0020528EFO:1001110
hypersensitivity pneumonitis2MONDO:0017853EFO:1001321
systemic sclerosis2MONDO:0005100EFO:0000717
temporal arteritis2MONDO:0008538EFO:1001209
breast neoplasm2MONDO:0021100MONDO:0007254
mucous membrane pemphigoid2MONDO:0018746EFO:1000680
lichen planus2MONDO:0006572EFO:1000726
uveitis2MONDO:0020283EFO:1001231
sinusitis2MONDO:0005961EFO:0007486
type 2 diabetes mellitus2MONDO:0005148MONDO:0005148
familial lipoprotein lipase deficiency2MONDO:0009387MONDO:0009387
Duchenne muscular dystrophy2MONDO:0010679MONDO:0010679
cardiomyopathy2MONDO:0004994EFO:0000318
Sjogren syndrome2MONDO:0010030EFO:0000699
osteoarthritis, knee2MONDO:0005416EFO:0004616
sensorineural hearing loss disorder2MONDO:0020678EFO:1001176
lymphoid leukemia2MONDO:0005402EFO:0004289
lipoma1MONDO:0005106EFO:0000759
age-related macular degeneration1MONDO:0005150EFO:0001365
Bell’s palsy1MONDO:0005665EFO:0007167
neoplasm1MONDO:0005070MONDO:0004992

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 506.

Phase distribution

PhaseTrials
PHASE3133
PHASE4123
PHASE2107
Not specified63
PHASE129
PHASE2/PHASE324
PHASE1/PHASE224
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03760835PHASE4RECRUITINGCongenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT03781700PHASE4RECRUITINGEvaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy
NCT04371445PHASE4RECRUITINGDextenza in the Post-op Management of Vitreoretinal Surgeries
NCT04549935PHASE4RECRUITINGThe PRIME Study: A Randomized, Controlled, Prospective Study
NCT05191706PHASE4RECRUITINGEvaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05331664PHASE4RECRUITINGDropless Pars Plana Vitrectomy Study
NCT05412394PHASE4RECRUITINGOnce Weekly Infant Corticosteroid Trial for DMD
NCT05725512PHASE4RECRUITINGPrednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06040255PHASE4ENROLLING_BY_INVITATIONFocal Cerebral Arteriopathy Steroid Trial
NCT06611696PHASE4RECRUITINGAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
NCT06654934PHASE4NOT_YET_RECRUITINGPrednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
NCT06676384PHASE4RECRUITINGWhich of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
NCT06943482PHASE4NOT_YET_RECRUITINGComparing Effectiveness of Steroids and Methotrexate in Treatment of Chronic Inflammatory Breast Disease
NCT07221838PHASE4RECRUITINGA Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07227428PHASE4NOT_YET_RECRUITINGComparison of Glucocorticoid Tapering Schedules in Rheumatoid Arthritis
NCT07252271PHASE4NOT_YET_RECRUITINGVery Low Dose Prednisolone on Newly Diagnosed Rheumatoid Arthritis
NCT07258771PHASE4RECRUITINGUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
NCT00138970PHASE4COMPLETEDCalcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
NCT00198978PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198991PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004PHASE4COMPLETEDTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199017PHASE4COMPLETEDGerman Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT00199056PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199082PHASE4COMPLETEDNewly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT00261820PHASE4COMPLETEDStudy Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
NCT00311961PHASE4COMPLETEDIntravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
NCT00312325PHASE4COMPLETEDEffect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans
NCT00393367PHASE4COMPLETEDBudesonide Inhalation Suspension for Acute Asthma in Children
NCT00445081PHASE4COMPLETEDPrednisolone vs. Ciclosporine in Severe Atopic Eczema
NCT00494624PHASE4UNKNOWNEfficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children
NCT00510263PHASE4COMPLETEDScandinavian Bell’s Palsy Study
NCT00526409PHASE4COMPLETEDLAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
NCT00609752PHASE4UNKNOWNAdverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn’s Disease
NCT00627731PHASE4COMPLETEDOral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
NCT00632554PHASE4COMPLETEDThe Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
NCT00662298PHASE4COMPLETEDPrednisolone Pharmacokinetics in Severe Asthma
NCT00689078PHASE4COMPLETEDEvaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
NCT00744666PHASE4UNKNOWNIntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids
NCT00778596PHASE4UNKNOWNPrednisolone Priming Study in Patients With Chronic Hepatitis B

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
NT5C2 R238WChildhood Acute Lymphocytic LeukemiaResistanceCytarabine + Gemcitabine + Doxorubicin + PrednisoloneCIViC DEID7816
NT5C2 R367QChildhood Acute Lymphocytic LeukemiaResistanceCytarabine + Gemcitabine + Prednisolone + DoxorubicinCIViC DEID7815
NT5C2 S445FChildhood Acute Lymphocytic LeukemiaResistanceCytarabine + Doxorubicin + Gemcitabine + PrednisoloneCIViC DEID7817

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 4 clinical and 21 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

179 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ENZALUTAMIDEChEMBL + PubChemPhase 4 (approved)NR3C1, NR3C2
EPLERENONEChEMBL + PubChemPhase 4 (approved)NR3C1, NR3C2
FLUDROCORTISONEChEMBL + PubChemPhase 4 (approved)NR3C1, NR3C2
BUDESONIDEChEMBLPhase 4 (approved)NR3C1, NR3C2
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1, NR3C2
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1, NR3C2
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1, NR3C2
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C1, NR3C2
HYDROCORTISONE BUTYRATEChEMBLPhase 4 (approved)NR3C1, NR3C2
MEDROXYPROGESTERONEChEMBLPhase 4 (approved)NR3C1, NR3C2
MIFEPRISTONEChEMBLPhase 4 (approved)NR3C1, NR3C2
PROGESTERONEChEMBLPhase 4 (approved)NR3C1, NR3C2
SPIRONOLACTONEChEMBLPhase 4 (approved)NR3C1, NR3C2
ASOPRISNILChEMBLPhase 3NR3C1, NR3C2
BALCINRENONEChEMBLPhase 3NR3C1, NR3C2
METRIBOLONEChEMBLPhase 2NR3C1, NR3C2
ONAPRISTONEChEMBLPhase 2NR3C1, NR3C2
STANOLONEChEMBLPhase 2NR3C1, NR3C2
TUROFEXORATE ISOPROPYLChEMBLPhase 2NR3C1, NR3C2
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot